Iovance Biotherapeutics (IOVA)

• Market cap: $1.02B
• 1 day: 1.59%
• 5 days: 14.29%
• 1 month: 4.92%
• 3 months: 16.36%
• 6 months: 25.49%
• Year to date: -67.14%
• 1 year: -64.74%
• 5 years: -94.59%
• 10 years: -66.62%
• Sector: Healthcare
• Industry: Biotechnology

About: Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Employees: 838